EUVIMEDEUVIMED entdecken
Crossref

The Safety of Dengvaxia and Should Hospitalization be an Outcome for its Clinical Trial?

Godofreda Vergeire-Dalmacion

Pharmaceutics and Pharmacology Research · 2018

DOI: 10.31579/2693-7247/003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics and Pharmacology Research, 2018. Verfasst von Godofreda Vergeire-Dalmacion.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The uncertainties on the efficacy and safety of Dengvaxia continue to haunt doctors, parents, and lawmakers alike in the Philippines. After the mass immunization of about 850,000 children with Dengvaxia, there has been a continuing report of deaths, unofficially 29 to date among those who received the vaccine between 2016-2017. Countries in the Asia Pacific region, including the Philippines, were one of the sites for the Dengvaxia Clinical Trial. In 2014, the Efficacy Trial of Dengvaxia covering the period after completion of the 3 doses up to the 28th day was published by Capeding, et al. An overall efficacy rate of 56.5% was reported but it can be misleading since the efficacy rates for each serotype varied widely. The uncertainties on the efficacy and safety of Dengvaxia continue to haunt doctors, parents, and lawmakers alike in the Philippines. After the mass immunization of about 850,000 children with Dengvaxia, there has been a continuing report of deaths, unofficially 29 to date among those who received the vaccine between 2016-2017. Countries in the Asia Pacific region, including the Philippines, were one of the sites for the Dengvaxia Clinical Trial. In 2014, the Efficacy Trial of Dengvaxia covering the period after completion of the 3 doses up to the 28th day was published by Capeding, et al. An overall efficacy rate of 56.5% was reported but it can be misleading since the efficacy rates for each serotype varied widely. The uncertainties on the efficacy and safety of Dengvaxia continue to haunt doctors, parents, and lawmakers alike in the Philippines. After the mass immunization of about 850,000 children with Dengvaxia, there has been a continuing report of deaths, unofficially 29 to date among those who received the vaccine between 2016-2017. Countries in the Asia Pacific region, including the Philippines, were one of the sites for the Dengvaxia Clinical Trial. In 2014, the Efficacy Trial of Dengvaxia covering the period after completion of the 3 doses up to the 28th day was published by Capeding, et al. An overall efficacy rate of 56.5% was reported but it can be misleading since the efficacy rates for each serotype varied widely.

Zitieren

APA

Vergeire-Dalmacion, G. (2018). The Safety of Dengvaxia and Should Hospitalization be an Outcome for its Clinical Trial?. Pharmaceutics and Pharmacology Research. https://doi.org/10.31579/2693-7247/003

Vancouver

Vergeire-Dalmacion G. The Safety of Dengvaxia and Should Hospitalization be an Outcome for its Clinical Trial?. Pharmaceutics and Pharmacology Research. 2018. doi:10.31579/2693-7247/003

BibTeX
@article{VergeireDalmacion2018,
  author = {Vergeire-Dalmacion, Godofreda},
  title = {The Safety of Dengvaxia and Should Hospitalization be an Outcome for its Clinical Trial?},
  journal = {Pharmaceutics and Pharmacology Research},
  year = {2018},
  doi = {10.31579/2693-7247/003}
}
Kostenlos starten →